One Case of Rhabdomyolysis in Patients with Chronic Kidney Disease Caused by Benzafibrate Tablets

doi:10.19803/j.1672-8629.20240764

Abstract

Abstract: Objective To analyze the risk of benzafibrate-associated rhabdomyolysis in patients with chronic kidney disease (CKD) so as to provide a reference for safe clinical use. Methods One case of CKD who developed rhabdomyolysis following bezafibrate administration was analyzed while related literature published over the past five years was reviewed to find out more about the clinical characteristics and outcomes in this population. Results Bezafibrate was possibly a risk factor for rhabdomyolysis in CKD patients, but the prognosis was good after symptomatic and supportive treatment. Conclusion Patients with end-stage renal disease are at higher risk of bdomyolysis caused by benzabate and the prognosis is undesirable. Serum drug concentrations have to be monitored and the dosage adjusted when needed.

Key words: Benzafibrate Tablets, Chronic Kidney Disease, Rhabdomyolysis, Adverse Drug Reactions

CLC Number:

R977
R994.11

LI Dan, YANG Xiongwen, CHEN Danjun, FU Chengxiao, YANG Bo. One Case of Rhabdomyolysis in Patients with Chronic Kidney Disease Caused by Benzafibrate Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 1049-1050.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240764

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I9/1049

References

[1] BAEZA-TRINIDAD R.Rhabdomyolysis: a syndrome to be Considered[J]. Medicina Clínica. 2022, 158(6): 277-283.
[2] YUAN LY, GAN H.Relationship between Lipid Metabolism and Prognosis in Haemodialysis Patients[J]. Journal of Chronic Disease(慢性病学杂志), 2024, 25(5): 641-646.
[3] Expert Group of Shanghai Clinical Quality Control Center for Nephrology. Guidelines for Early Screening, Diagnosis, Prevention, and Treatment of Chronic Kidney Disease (2022 Edition)[J]. Chinese Journal of Nephrology(中华肾脏病杂志), 2022, 38(5): 453-464.
[4] WU J, SONG Y, LI H, et al.Rhabdomyolysis Associated with Fibrate Therapy: Review of 76 Published Cases and a New Case Report[J]. European Journal of Clinical Pharmacology, 2009, 65(12): 1169-1174.
[5] KOBAYASHI D, HOSAKA S, INOUE E, et al.Quantitative Evaluation of Initial Symptoms as Predictors to Detect Adverse Drug Reactions Using Bayes' Theory: Expansion and Evaluation of Drug-Adverse Drug Reaction-Initial Symptom Combinations Using Adverse Event Reporting System Database[J]. Biological & Pharmaceutical Bulletin, 2013, 36(12): 1891-1901.
[6] WU Q, XU HS, CHEN YH, et al.A Case of Rhabdomyolysis, Hepatic and Renal Impairment Caused by Benzafibrate Tablets[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(11): 1283-1285.
[7] XU ZF.Nursing Care of a Case of Rhabdomyolysis Caused by Benzafibrate in a Patient with Type 2 Diabetes Mellitus[J]. Contemporary Nurses
(当代护士), 2020, 27(10): 106-107.
[8] ZENG W, TOMLINSON B.Causes and Outcome of Rhabdomyolysis in Patients Admitted to Medical Wards in the Prince of Wales Hospital[J]. Annals of Translational Medicine, 2021, 9(16): 1329.
[9] WANG SQ, XU WT, ZHOU DM.Analysis of Four Cases of Acute Rhabdomyolysis Caused by Lipid-Lowering Therapy in Maintenance Haemodialysis Patients[J]. Journal of Fujian Medical University(福建医科大学学报), 2017, 51(2): 130-131.
[10] MI MD, GONG JY, SUN WJ, et al.Evaluation of the Clinical Application of Five Formulas for Estimating Glomerular Filtration Rate for the Assessment of Renal Filtration Function[J]. Journal of Clinical Investigation(临床检验杂志), 2024, 42(6): 456-460.
[11] STEINMEYER J, FLECHTENMACHER J.Drug-Induced Myopathies[J]. Zeitschrift für Orthopädie und Unfallchirurgie, 2023, 161(2): 175-181.
[12] IMAI E, IMAI A.Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease[J]. JMA Journal, 2022, 5(3): 328-333.
[13] OSTROWSKI P, BONCZAR M, AVRAM AE, et al.Safety Monitoring of Drug-Induced Muscle Injury and Rhabdomyolysis: a Biomarker-Guided Approach for Clinical Practice and Drug Trials[J]. Clinical Chemistry and Laboratory Medicine, 2023, 61(10): 1688-1699.
[14] LIN J, HE Y, RU C, et al.Advancing Adverse Drug Reaction Prediction with Deep Chemical Language Model for Drug Safety Evaluation[J]. International Journal of Molecular Sciences, 2024, 25(8): 4516.
[15] BIN DAYEL FF, ALFIREVIC A, CHADWICK AE.Developing in vitro Models to Define the Role of Direct Mitochondrial Toxicity in Freq-uently Reported Drug-Induced Rhabdomyolysis[J]. Biomedicines, 2023, 11(5): 1485.
[16] TSUBAKI M, TAKEDA T, MASTUDA T, et al. Combination Treatment with Statins and Bezafibrate Induces Myotoxicity via Inhibition of Geranylgeranyl Pyrophosphate Biosynthesis and Rho Activation in L6 Myoblasts and Myotube Cells[J]. Journal of Physiology and Pharmacology, 2022, 73(1): 10.26402.